Essential Strategies for Optimizing the Use of Long-Acting Treatments in Schizophrenia

Long-acting injectable antipsychotics (LAIs) play a crucial role in the treatment of schizophrenia, offering improved adherence and stability for many patients. This session will provide an in-depth review of the latest clinical and real-world data on LAIs versus oral antipsychotics, helping clinicians make informed treatment decisions. Attendees will gain insights into the pharmacologic profiles and practical considerations of available LAIs to support optimal, individualized treatment selection. Additionally, the session will explore effective communication strategies—both in person and via telemedicine—to enhance patient engagement and acceptance of LAI treatment. Join us for a practical and evidence-based discussion on optimizing schizophrenia management with LAIs.

Supported by educational grants from Alkermes, Inc.; Janssen Pharmaceuticals, Inc., administered by JanssenScientific Affairs, LLC: a Johnson & Johnson Company; and Teva Pharmaceuticals, USA, Inc.